Skip to main content

Table 1 Characteristics of NSCLC patients in the study cohort

From: Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer

  

Total (%)

E2A-PBX1 positive (%)

E2A-PBX1 negative (%)

P value

Median overall survival (95% CI)

P value

 

Total

184 (100)

23 (12.5)

161 (87.5)

 

105.60 (55.41 ~ 155.79)

 

Age

      
 

Mean (years)

66.9 ± 12.0

66.0 ± 11.7

67.0 ± 12.1

0.698*

  
 

Range (years)

25-91

39-84

25-91

   
 

<71

109 (100)

13 (11.9)

96 (88.1)

0.777

69.00 (43.73 ~ 94.27)

0.7069

 

≥71

75 (100)

10 (13.3)

65 (86.7)

 

105.60 (18.53 ~ 192.67)

 

Gender

   

0.215

  
 

Male

78 (100)

7 (9.0)

71 (91.0)

 

64.70 (NA)

0.0889

 

Female

106 (100)

16 (15.1)

90 (84.9)

 

105.60 (57.58 ~ 153.62)

 

Race

   

0.606

 

0.1430

 

Caucasian

136 (100)

17 (12.5)

119 (87.5)

 

81.70 (52.59 ~ 110.81)

 
 

Asian

27 (100)

3 (11.1)

24 (88.9)

 

64.70 (45.79 ~ 83.61)

 
 

Hispanic

7 (100)

2 (28.6)

5 (71.4)

 

NR

 
 

African-American

7 (100)

0

7 (100)

 

NR

 
 

Others

7 (100)

1 (14.3)

6 (85.7)

   

Smoking

   

0.174

 

0.0868

 

Smoker

127 (100)

19 (15.0)

108 (85.0)

 

69.00 (42.36 ~ 95.64)

 
 

Non-smoker

53 (100)

4 (7.5)

49 (92.5)

 

105.60 (35.86 ~ 175.34)

 
 

Unknown

4 (100)

0

4 (100)

   

Pack/Year (smoker)

      
 

Mean

41.6 ± 23.5

46.3 ± 26.7

30.9 ± 35.9

0.623*

  
 

Range

1-160

5-90

1-160

   

Gender × Smoking

   

0.097

 

0.0258

 

Male, Smoker

59 (100)

5 (8.5)

54 (91.5)

0.7331

56.20 (27.25 ~ 85.15)

0.07491

 

Male, Non-smoker

18 (100)

2 (11.1)

16 (88.9)

 

NR

 
 

Female, Smoker

68 (100)

14 (20.6)

54 (79.4)

0.0482

81.70 (41.68 ~ 121.72)

0.67142

 

Female, Non-smoker

35 (100)

2 (5.7)

33 (94.3)

 

105.60 (35.04 ~ 176.16)

 
 

Unkown

4 (100)

0

4 (100)

   

Histology

   

0.276

 

0.6013

 

AIS

76 (100)

17 (22.4)

59 (77.6)

0.0063

105.60 (57.93 ~ 153.27)

0.12083

 

Invasive adenocarcinoma

76 (100)

5 (6.6)

71 (93.4)

 

53.10 (NA)

 
 

Squamous cell carcinoma

18 (100)

0

18 (100)

 

NR

 
 

Carcinoid

6 (100)

0

6 (100)

 

NR

 
 

Large

4 (100)

1 (25.0)

3 (75.0)

 

NR

 
 

Others

4 (100)

0

4 (100)

   

Tumor Size

   

0.026*

  
 

Mean

3.3 ± 1.9

4.1 ± 2.8

3.2 ± 1.7

   
 

Range

0.5-13.0

0.9-12.0

0.5-13.0

   

Pathological TNM Classification

      

pt

pt1

74 (100)

9 (12.2)

65 (87.8)

0.408

105.60 (NA)

0.0915

 

pt2

81 (100)

9 (11.1)

72 (88.9)

 

69.00 (44.22 ~ 93.78)

 
 

pt3

8 (100)

0

8 (100)

 

40.20 (26.06 ~ 54.34)

 
 

pt4

18 (100)

4 (22.2)

14 (77.8)

 

30.50 (NA)

 
 

Unknown

3 (100)

1 (33.3)

2 (66.6)

   

pn

pn0

144 (100)

18 (12.5)

126 (87.5)

0.924

105.60 (65.68 ~ 145.52)

0.0038

 

pn1

19 (100)

3 (15.8)

16 (84.2)

 

47.80 (32.55 ~ 63.05)

 
 

pn2

17 (100)

2 (11.8)

15 (88.2)

 

45.50 (NA)

 
 

pn3

2 (100)

0

2 (100)

 

5.20 (NA)

 
 

Unknown

2 (100)

0

2 (100)

   

pm

pm0

171 (100)

20 (11.7)

151(88.3)

0.179

105.60 (55.99 ~ 155.21)

0.2605

 

pm1

12 (100)

3 (25.0)

9 (75.0)

 

56.20 (35.26 ~ 77.14)

 

Pathological Stage

   

0.426

 

0.0167

 

Stage I

119 (100)

13 (10.9)

106 (89.1)

 

105.60 (65.47 ~ 145.73)

 
 

Stage II

22 (100)

2 (9.1)

20 (90.9)

 

NR

 
 

Stage III

29 (100)

5 (17.2)

24 (82.8)

 

33.60 (0.00 ~ 73.11)

 
 

Stage IV

12 (100)

3 (25.0)

9 (75.0)

 

56.20 (35.26 ~ 77.14)

 
 

Unknown

2 (100)

0

2 (100)

   

Recurrence

   

0.435

 

<0.001

 

Yes

63 (100)

6 (9.5)

57 (90.5)

 

39.30 (30.45 ~ 48.15)

 
 

No

103 (100)

14 (13.6)

89 (86.4)

 

NR

 
 

Unknown

18 (100)

1 (5.6)

17 (94.4)

   
  1. * student t test.
  2. 1 between male smoker and male non-smoker.
  3. 2 between female smoker and female non-smoker.
  4. 3 between AIS and invasive adenocarcinoma.
  5. AIS: adenocarcinoma in situ; NR: not reached; NA: not available.